Rigel's Fostamatinib and the Future of Rheumatoid Arthritis Therapy

Thu Jul 12, 2012 7:00am EDT

* Reuters is not responsible for the content in this press release.

Discussing Rigel Pharmaceutical's (NASDAQ:RIGL) immunomodulatory Rheumatoid Arthritis (RA) treatment, CEO Jim Gower says it has the potential to replace TNF inhibitors as the standard-of-care, with earlier results, broader efficacy, and dramatic improvement in bone destruction - a hallmark of the disease.

"The Pfizer (NYSE:PFE) drug [tofacitinib] and our drug, Fostamatinib, both work in the same week of therapy, they have differentiated mechanisms, they're both oral, so they make a lot more sense in terms of where you turn in the early [RA] treatment. Of the TNF inhibitors, which are in the fourth, and beginning to be fifth generation, it's hard to find any that have been introduced early that haven't been at least a billion dollar product."
In an exclusive interview with PropThink.com, Gower discusses the future of Fostamatinib - partnered with Astrazeneca (NYSE:AZN) - and promising pipeline asthma treatment R343, as well as Rigel's financial situation and catalysts for the company in the next year.

Click Here To View The Exclusive Video Interview with Rigel Pharmaceuticals.

About PropThink

PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more visit us at http://propthink.com

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PropThink via Thomson Reuters ONE

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.